文献速递肿瘤 PET/CT骨显像与常规 SPECT核素与放射性配体治疗

68Ga-PSMA PET/CT在前列腺癌骨转移评估中的应用

68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-01-23

该回顾性分析纳入140例前列腺癌患者的152次PET/CT扫描,比较68Ga-PSMA PET与低剂量CT对骨转移的检出,并获取半定量与定量参数。结果显示68Ga-PSMA PET阳性骨病灶显著多于CT阳性病灶,且PSA水平与多个68Ga-PSMA PET参数显著相关。作者认为68Ga-PSMA PET/CT是检出前列腺癌骨转移的有用诊断工具。

要点

  • 68Ga-PSMA PET阳性骨病灶显著多于低剂量CT阳性病灶。
  • PSA水平与骨转移灶的SUV、K1、k3、Ki及分布异质性显著相关。
  • 68Ga-PSMA PET/CT是检出前列腺癌骨转移的有用诊断工具。

核心结论

  • 68Ga-PSMA PET/CT是检出前列腺癌骨转移的有用诊断工具。
  • 68Ga-PSMA PET显示的骨转移灶多于低剂量CT。
  • PSA血浆水平与多个68Ga-PSMA PET参数显著相关。

研究设计与样本

  • 回顾性分析,共评估140例前列腺癌患者的152次PET/CT扫描。
  • 30例为既往未治疗的原发性前列腺癌,110例为原发性前列腺癌治疗后生化复发。
  • 所有患者接受盆腔及下腹部动态PET/CT以及68Ga-PSMA-11全身PET/CT。
  • PET/CT扫描进行定性(视觉)、半定量(SUV)以及基于两组织室模型和非室室方法的定量分析,提取分形维数。
  • 差异以p值<0.05为显著。

主要发现

  • 在37例患者(8例原发性前列腺癌,29例生化复发)中共检出168个68Ga-PSMA阳性骨病灶和113个CT阳性骨病灶。
  • 168个病灶中,103个同时为68Ga-PSMA PET阳性且CT阳性,65个仅68Ga-PSMA阳性,10个仅CT阳性。
  • Yang检验显示68Ga-PSMA PET阳性病灶显著多于CT阳性病灶。
  • 关联分析显示PSA血浆水平与骨转移灶的多个68Ga-PSMA-11相关参数显著相关,包括示踪剂摄取程度(SUVaverage和SUVmax)、从血浆到间质/细胞内室的转运率(K1)、与PSMA受体结合及内化率(k3)、流入率(Ki)以及分布异质性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aims of this retrospective analysis were to compare 68Ga-PSMA PET findings and low-dose CT findings (120 kV, 30 mA), and to obtain semiquantitative and quantitative 68Ga-PSMA PET data in patients with prostate cancer (PC) bone metastases. METHODS: In total, 152 PET/CT scans from 140 patients were evaluated. Of these patients, 30 had previously untreated primary PC, and 110 had biochemical relapse after treatment of primary PC. All patients underwent dynamic PET/CT scanning of the pelvis and lower abdomen as well as whole-body PET/CT with 68Ga-PSMA-11. The PET/CT scans were analysed qualitatively (visually), semiquantitatively (SUV), and quantitatively based on a two-tissue compartment model and a noncompartmental approach leading to the extraction of the fractal dimension. Differences were considered significant for p values <0.05. RESULTS: In total, 168 68Ga-PSMA-positive and 113 CT-positive skeletal lesions were detected in 37 patients (8 with primary PC, 29 with biochemical recurrence). Of these 168 lesions, 103 were both 68Ga-PSMA PET-positive and CT-positive, 65 were only 68Ga-PSMA-positive, and 10 were only CT-positive. The Yang test showed that there were significantly more 68Ga-PSMA PET-positive lesions than CT-positive lesions. Association analysis showed that PSA plasma levels were significantly correlated with several 68Ga-PSMA-11-associated parameters in bone metastases, including the degree of tracer uptake (SUVaverage and SUVmax), its transport rate from plasma to the interstitial/intracellular compartment (K1), its rate of binding to the PSMA receptor and its internalization (k3), its influx rate (Ki), and its distribution heterogeneity. CONCLUSION: 68Ga-PSMA PET/CT is a useful diagnostic tool in the detection of bone metastases in PC. 68Ga-PSMA PET visualizes more bone metastases than low-dose CT. PSA plasma levels are significantly correlated with several 68Ga-PSMA PET parameters.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sachpekidis C, Bäumer P, Kopka K, et al. 68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 29362859. doi:10.1007/s00259-018-3936-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。